GLP-1 Receptor Agonists and the Path to Sustainable Obesity Care
This Viewpoint discusses the optimal treatment duration of glucagon-like peptide-1 receptor agonists in people with obesity and the benefits of off-ramping, the tapering of these antiobesity medications following an initial treatment period.
Authors
- François Venter (ORCID: https://orcid.org/0000-0002-4157-732X)
- Felix Teufel (ORCID: https://orcid.org/0000-0002-5293-4783)
- Jennifer Manne‐Goehler (ORCID: https://orcid.org/0000-0001-9295-0035)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Emory University (US)
- University of the Witwatersrand (ZA)
- Massachusetts General Hospital (US)
- University of Pretoria (ZA)
Publication Details
- Journal
- JAMA Internal Medicine
- Published
- 2024-10-14
- DOI
- https://doi.org/10.1001/jamainternmed.2024.3579
- Citations
- 20
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 8.96